2-Pyridin-2-ylmethyl-piperazine-1,2,4-tricarboxylic acid 1-benzyl ester 4-tert-butyl ester 2-methyl ester | 218952-60-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Pyridin-2-ylmethyl-piperazine-1,2,4-tricarboxylic acid 1-benzyl ester 4-tert-butyl ester 2-methyl ester
• 英文别名: 2-pyridin-2-ylmethyl-piperazine-1,2,4-tricarboxilic acid 1-benzyl ester 4-tert-butyl ester 2-methyl ester；1-O-benzyl 4-O-tert-butyl 2-O-methyl 2-(pyridin-2-ylmethyl)piperazine-1,2,4-tricarboxylate
• CAS: 218952-60-4
• 化学式: C₂₅H₃₁N₃O₆
• 分子量: 469.538
• InChiKey: IJDHWFRFXYUYTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  98.3
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-Pyridin-2-ylmethyl-piperazine-1,2,4-tricarboxylic acid 1-benzyl ester 4-tert-butyl ester 2-methyl ester 在 palladium 10% on activated carbon 作用下， 以 甲醇 为溶剂， 反应 48.0h， 以61%的产率得到3-Pyridin-2-ylmethyl-piperazine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester
  参考文献：
  名称：

  Combinations of &bgr;3 agonists and growth hormone secretagogues

  摘要：

  这项发明涉及包括β3肾上腺素受体激动剂在内的药物组合物，其中包括(4-(2-(2-(6-氨基吡啶-3-基)-2(R)-羟乙基氨基)乙氧基)苯乙酸)和生长激素或生长激素促分泌剂，以及这些化合物或其前药的药用可接受盐。该发明还涉及使用这些组合物治疗动物中的肥胖、糖尿病、高血压和衰弱，特别是在人类中的方法。

  公开号：

  US06657063B1
• 作为产物：
  描述：

  (+/-)-1-苄氧羰基-4-Boc-哌嗪-2-羧酸甲酯 在 双(三甲基硅烷基)氨基钾 、 碳酸氢钠 作用下， 以 四氢呋喃 、 N,N-二甲基甘氨酸 、 乙酸乙酯 为溶剂， 生成 2-Pyridin-2-ylmethyl-piperazine-1,2,4-tricarboxylic acid 1-benzyl ester 4-tert-butyl ester 2-methyl ester
  参考文献：
  名称：

  Dipeptide derivatives as growth hormone secretagogues

  摘要：

  本发明涉及公式化合物及其药用盐，其中取代基如规范中定义，这些化合物是生长激素分泌素，能增加内源性生长激素水平。本发明的化合物可用于治疗和预防骨质疏松症和/或虚弱、充血性心力衰竭、与衰老有关的虚弱、肥胖；加速骨折修复、减轻重大手术后蛋白质分解反应、减少慢性疾病导致的消瘦和蛋白质丢失、加速伤口愈合，或加速烧伤患者或接受重大手术的患者的康复；改善肌肉力量、运动能力、皮肤厚度的维持、代谢稳态或肾脏稳态。本发明的化合物在与：双膦酸盐类化合物如阿伦膦酸盐；雌激素、前马品、以及可选的孕激素；雌激素拮抗剂或激动剂；或降钙素结合使用时，也可用于治疗骨质疏松症和/或虚弱；及其药用组合物。此外，本发明涉及药用组合物，用于增加人类或其他动物内源性生长激素的产生或释放，包括本发明的化合物和从GHRP-6、Hexarelin、GHRP-1、生长激素释放因子（GRF）、IGF-1、IGF-2或B-HT920中选择的生长激素分泌素的有效量。该发明还涉及在制备公式I化合物中有用的中间体。

  公开号：

  US06251902B1

文献信息

• Dipeptide derivatives as growth hormone secretagogues
  申请人：Pfizer Inc.

  公开号：US06251902B1

  公开（公告）日：2001-06-26

  This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis and/or frailty when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed to intermediates useful in the preparation of compounds of Formula I.

  本发明涉及公式化合物及其药用盐，其中取代基如规范中定义，这些化合物是生长激素分泌素，能增加内源性生长激素水平。本发明的化合物可用于治疗和预防骨质疏松症和/或虚弱、充血性心力衰竭、与衰老有关的虚弱、肥胖；加速骨折修复、减轻重大手术后蛋白质分解反应、减少慢性疾病导致的消瘦和蛋白质丢失、加速伤口愈合，或加速烧伤患者或接受重大手术的患者的康复；改善肌肉力量、运动能力、皮肤厚度的维持、代谢稳态或肾脏稳态。本发明的化合物在与：双膦酸盐类化合物如阿伦膦酸盐；雌激素、前马品、以及可选的孕激素；雌激素拮抗剂或激动剂；或降钙素结合使用时，也可用于治疗骨质疏松症和/或虚弱；及其药用组合物。此外，本发明涉及药用组合物，用于增加人类或其他动物内源性生长激素的产生或释放，包括本发明的化合物和从GHRP-6、Hexarelin、GHRP-1、生长激素释放因子（GRF）、IGF-1、IGF-2或B-HT920中选择的生长激素分泌素的有效量。该发明还涉及在制备公式I化合物中有用的中间体。
• Growth hormone secretagogues
  申请人：Pfizer Inc.

  公开号：US06358951B1

  公开（公告）日：2002-03-19

  This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery, improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis when used in combination with: a bisphosphonate compound such as alendronate, estrogen, premarin, and optionally progesterone: a &bgr;3 adrenergic receptor agonist; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefore. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920.

  本发明涉及以下化合物及其药用盐，其中取代基如规范中定义，这些化合物是生长激素分泌素，可增加内源性生长激素水平。本发明的化合物可用于治疗和预防骨质疏松症、充血性心力衰竭、与衰老相关的虚弱、肥胖；加速骨折修复、减轻重大手术后蛋白质分解反应、减少慢性疾病引起的消瘦和蛋白质流失、加速伤口愈合，或加速烧伤患者或接受重大手术的患者的康复，改善肌肉力量、运动能力、皮肤厚度维持、代谢稳态或肾功能稳态。本发明的化合物在与双膦酸盐化合物（如阿伦膦酸盐）、雌激素、孕马尿素和可选孕激素：β3肾上腺素受体激动剂；雌激素激动剂或拮抗剂；或降钙素结合使用时，对治疗骨质疏松症也具有用途，以及相应的药用组合物。此外，本发明涉及用于增加人类或其他动物内源性生长激素产生或释放的药用组合物，包括本发明的化合物和选择自GHRP-6、Hexarelin、GHRP-1、生长激素释放因子（GRF）、IGF-1、IGF-2或B-HT920的生长激素分泌素的有效量。
• Dipeptide derivatives
  申请人：Pfizer Inc.

  公开号：US06194578B1

  公开（公告）日：2001-02-27

  This invention is directed to compounds of the Formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are therapeutically effective in treating osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis and/or frailty when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions therapeutically effective for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed to intermediates useful in the preparation of compounds of Formula I.

  这项发明涉及公式化合物及其药用盐，其中取代基如规范中定义的那样，这些化合物是生长激素分泌素，可以增加内源性生长激素的水平。本发明的化合物在治疗骨质疏松症和/或虚弱、充血性心力衰竭、与衰老有关的虚弱、肥胖；加速骨折修复、减轻重大手术后蛋白质分解反应、减少慢性疾病引起的消瘦和蛋白质流失、加速伤口愈合，或加速烧伤患者或接受重大手术的患者的康复方面具有治疗效果；改善肌肉力量、运动能力、皮肤厚度的维持、代谢稳态或肾脏稳态。本发明的化合物在与双膦酸盐类化合物（如阿伦膦酸盐）、雌激素、孕马尿素和可选择的孕激素、雌激素激动剂或拮抗剂、降钙素一起使用时也可用于治疗骨质疏松症和/或虚弱；以及用于制备这些药物组合的药物组合。此外，本发明涉及药物组合，对于增加人类或其他动物内源性生长激素的产生或释放具有治疗效果，包括本发明化合物的有效量和从GHRP-6、Hexarelin、GHRP-1、生长激素释放因子（GRF）、IGF-1、IGF-2或B-HT920中选择的生长激素分泌素。该发明还涉及在制备公式I化合物时有用的中间体。
• USRE038524E1
  申请人：——

  公开号：——

  公开（公告）日：——
• DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES
  申请人：PFIZER INC.

  公开号：EP1001970A1

  公开（公告）日：2000-05-24